Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 09/06/2026			Varia. 5j.	Varia. 1 janv.
616,18 ^USD	+0,79 %		+2,20 %	-20,17 %

16:30	Ebola Bundibugyo : le point sur les vaccins et traitements en cours de développement	RE
08/06	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02:00 PM

Autres langues

16:30	What Bundibugyo Ebola vaccines and treatments are under development
04/06	What Bundibugyo Ebola vaccines and treatments are under development
04/06	Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
03/06	CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
28/05	Regeneron Pharmaceuticals' Ebola Antibody Recommended by WHO for Investigational Use in Bundibugyo Ebolavirus
28/05	Regeneron's Ebola antibody recommended by World Health Organization for investigational use in response to current Bundibugyo ebolavirus outbreak
28/05	Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
28/05	Regeneron Pharmaceuticals, Inc.'s Inmazeb And Maftivimab Recommended For Investigational Use In Bundibugyo Ebolavirus Outbreak
28/05	WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak
26/05	Wall Street ist zurück, Chips geben den Ton an
26/05	Wall Street regresa de la mano de los semiconductores
26/05	Wall Street Returns, Chips Lead
26/05	US biotech Regeneron to launch global capability centre in India's Hyderabad - statement
25/05	Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
22/05	Bundibugyo Ebola vaccines and treatments in development
22/05	Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment
22/05	Regeneron Pharmaceuticals - Lynozyfic Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
22/05	Otarmeni receives EMA filing acceptance for genetic hearing loss
22/05	Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
22/05	Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance For Otarmeni (Lunsotogene Parvec) For Genetic Hearing Loss
21/05	Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
21/05	Regeneron Pharmaceuticals, Inc. Demonstrates Lynozyfic Monotherapy Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
20/05	REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
19/05	Biopharmaceutical firm Parabilis Medicines files for US IPO
18/05	US Equity Indexes Off Session Lows as Trump Postpones Iran Attack